Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA.

J Infect Dis. 2019 May 17. pii: jiz149. doi: 10.1093/infdis/jiz149. [Epub ahead of print]

PMID:
31099835
2.

Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial.

Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, Das A, Skarinsky D, Eckburg PB, Ellis-Grosse EJ.

Clin Infect Dis. 2019 Mar 6. pii: ciz181. doi: 10.1093/cid/ciz181. [Epub ahead of print]

PMID:
30861061
3.

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02549-18. doi: 10.1128/AAC.02549-18. Print 2019 May.

PMID:
30858207
4.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):143-146. doi: 10.1016/j.diagmicrobio.2018.08.010. Epub 2018 Aug 28.

PMID:
30236530
5.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

6.

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.

Diep JK, Sharma R, Ellis-Grosse EJ, Abboud CS, Rao GG.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01815-17. doi: 10.1128/AAC.01815-17. Print 2018 Feb.

7.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

8.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Wenzler E, Ellis-Grosse EJ, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00775-17. doi: 10.1128/AAC.00775-17. Print 2017 Sep.

9.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5141-5. doi: 10.1128/AAC.00355-16. Print 2016 Sep.

10.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

11.

Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.

Ambrose PG, Hammel JP, Bhavnani SM, Rubino CM, Ellis-Grosse EJ, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1466-70. doi: 10.1128/AAC.01743-10. Epub 2011 Dec 12.

12.

Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL.

Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S103-10. doi: 10.1086/653057. Review.

PMID:
20597657
13.

Exposure-response analyses of tigecycline tolerability in healthy subjects.

Passarell J, Ludwig E, Liolios K, Meagher AK, Grasela TH, Babinchak T, Ellis-Grosse EJ.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9. doi: 10.1016/j.diagmicrobio.2009.06.019.

PMID:
19748422
14.

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28. doi: 10.1093/jac/dkn250.

PMID:
18684703
15.

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. Epub 2007 Oct 22.

16.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

17.

Moving goalposts--regulatory oversight of antibacterial drugs.

Brenner R, Ellis-Grosse EJ, Echols R.

Nat Biotechnol. 2006 Dec;24(12):1515-20.

PMID:
17160053
18.

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ.

J Antimicrob Chemother. 2006 Dec;58(6):1221-9. Epub 2006 Sep 29.

PMID:
17012300
19.

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.

Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E; Tigecycline 305 cSSSI Study Group.

Antimicrob Agents Chemother. 2005 Nov;49(11):4658-66.

20.
21.

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.

Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71. Review.

PMID:
16105560
22.

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53.

PMID:
16080072
23.

The pharmacokinetic and pharmacodynamic profile of tigecycline.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40. Review.

PMID:
16080071
24.

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.

Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group.

Clin Ther. 2004 May;26(5):704-14.

PMID:
15220014
25.

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.

Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP.

Hepatology. 2002 Nov;36(5):1197-205.

PMID:
12395330

Supplemental Content

Loading ...
Support Center